# US 2019/0315862 A1 · Methods and pharmaceutical compositions for the prophylactic treatment of metastases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315862 A1
- Document ID: US20190315862A1
- Status: Published application
- Kind: A1
- Application number: 16/462,754
- Filed: 2017-11-21
- Published: 2019-10-17
- Earliest claimed: 2016-11-21
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite De Strasbourg; Etablissement Francais Du Sang (Efs)
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Université De Strasbourg; Etablissement FrançAis Du Sang (Efs)
- Inventors: Pierre MANGIN; Christian GACHET
- Web page: https://patentgrep.com/patent/US20190315862A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61P 35/04: specific for metastasis
- C07K 14/70503: {Immunoglobulin superfamily}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2310/16: Aptamers
- C12N 2320/30: Special therapeutic applications
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.

## Claims

### Claim 1

A method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.

### Claim 2 (depends on 1)

The method of claim 1 for the prophylactic treatment of lung metastases.

### Claim 3 (depends on 1)

The method of claim 1 wherein the patient suffers from a breast cancer.

### Claim 4 (depends on 1)

The method of claim 1 wherein the agent is an antibody which is an antibody having specificity for GPVI or EMMPRIN.

### Claim 5 (depends on 4)

The method of claim 4 wherein the anti-GPVI antibody does not induce depletion of platelets.

### Claim 6 (depends on 4)

The method of claim 4 wherein the anti-GPVI antibody is a Fab fragment.

### Claim 7 (depends on 4)

The method of claim 4 wherein the anti-GPVI antibody comprises a heavy chain variable region comprising CDR1, CDR2 and CDR3 regions constituted of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 and a light chain variable region comprising CDR1, CDR2 and CDR3 regions constituted of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

### Claim 8 (depends on 1)

The method of claim 1 wherein the agent is an aptamer having specificity for GVPI or EMMPRIN.

### Claim 9 (depends on 1)

The method of claim 1 wherein the agent is a polypeptide which comprises an extracellular domain of GPVI or EMMPRIN optionally fused to an immunoglobulin constant domain (Fc region).
